Balmes discusses the latest annual State of the Air Report, which shows that 131 million Americans are living in areas with failing air quality grades.

In an interview with HCPLive, Larry Ereshefsky, PharmD, discussed the phase 3 RECOVER trial assessing brilaroxazine at 50 mg and 15 mg for acute schziophrenia.

Solomon explains how the health care system contributes to climate change and the direct health impacts seen as a result, based on her session at ACP.

Treatment with risankizumab was shown to be an effective strategy among patients with PsA regardless of varying demographic and psoriatic disease characteristics through 1 year.

Thoracic ultrasound examination may be applicable as a screening method for interstitial lung disease in patients with RA and respiratory symptoms.

After being prescribed another urate lowering therapy for ≥ 30 days, only 51.0% of patients were able to achieve SU < 6 mg/dL.

This segment of Hemming’s ACP interview featured a discussion of a website used to assess digital applications for patients struggling with mental health issues.

The first in our 3-part quiz series based on the NLA's 2024 update to their 2019 scientific statement on use of lipoprotein(a) in clinical practice focuses on basic considerations surrounding Lp(a) measurement.

A new study found female patients (8.15%) had a lower mortality rate when treated by female physicians than male physicians (8.38%).

Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.

Rilzabrutinib led to a durable platelet response in adult patients with persistent or chronic immune thrombocytopenia in the LUNA 3 study.

Experts discuss the use of biosimilars in treating neovascular age-related macular edema (nAMD) and diabetic macular edema (DME).

Branch provides an overview of the use of dual antiplatelet therapy and anticoagulants based on his session at the ACP Internal Medicine meeting.

Experts discuss the safety of aflibercept 8 mg, emphasizing familiarity, efficacy, and durability, supported by reassuring data from the two-year PULSAR and PHOTON studies.

Another segment of her ACP 2024 interview featured a discussion on weight loss drugs, healthy living, and discussions with patients.

NBI-1065845 shows promise in alleviating symptoms of major depressive disorder in patients with inadequate response to current antidepressant treatments, according to phase 2 SAVITRI study data.

A new study found the perceived onset of old age rose nearly 3 years from 1911 to 1953.

Shah discusses the prevalence of psychiatric illness among hospitalized patients and highlights key considerations for their management from her session at ACP.

The expert panel addresses the common assumption of medication non-adherence in patients with resistant diabetes, provides strategies to differentiate non-adherence from underlying comorbidities contributing to resistance, and discusses the challenges of patients who are post-metabolic surgery, yet experience weight gain and symptom recurrence.

Hanford Yau, MD, Ralph DeFronzo, MD, Pam Kushner, MD, Honey East, MD, and Christopher Lucci, MD, explore resistant diabetes, share their clinical experience regarding the frequency of this condition, and highlight the role of continuous glucose monitoring in identifying patients who may be resistant, as indicated by prolonged periods of blood glucose levels outside the target range.

The national registry-based analysis in Denmark may inform the clinical value of medication adherence in the first years of glaucoma treatment.

Eblasakimab shows promising itch relief in dupilumab-experienced atopic dermatitis patients, with significant reductions in symptoms observed.

Announced on April 18, the approval is based on the VISIBLE 2 trial and comes less than 7 months after the approval of SC vedolizumab in ulcerative colitis.

Post-treatment with risankizumab, the cDAPSA score, PGA score, and PASI score substantially decreased among a cohort of patients with psoriatic arthritis.